SMC approves first two ‘ultra-orphan’ pathway meds
admin 11th February 2020 Uncategorised 0The process is intended for for extremely rare conditions. More: SMC approves first two ‘ultra-orphan’ pathway meds Source: News
read more
The process is intended for for extremely rare conditions. More: SMC approves first two ‘ultra-orphan’ pathway meds Source: News
read moreWith its $63 billion merger with Allergan nearly consummated, AbbVie has touted a suite of the Irish drugmaker’s top performers as growth drivers. One area where AbbVie has less hope? Allergan’s medical aesthetics unit—and another weak quarter won’t soothe the deal
read moreWhat do you get when you add a drug with clear clinical benefits, an extremely early FDA nod and two well-prepared sales teams? In Daiichi Sankyo and AstraZeneca’s HER2-targeting med Enhertu’s case, a potential $18 million in sales during the
read moreDr. Reddy’s has spent nearly five years trying to get out from under a warning letter for an important API plant in India but has yet to shake off all of the FDA’s concerns. In fact, a new FDA filing
read moreDespite facing a highly touted competitor in Novartis’ Beovu, Regeneron hasn’t broken a sweat as blockbuster eye med Eylea continues to gobble up the market. Already in the lead in multiple indications, new two-year data could help Regeneron make the
read moreUtah is sending employees to Mexico to save on drug costs making clear states are willing to get creative to save on pharmaceuticals. Elsewhere, pharma is again a political target, and one industry watchers how President Donald Trump will position
read more© 1994 - 2026 B.M. Pharmaceuticals